Characteristic | Â | Controls | DILI cases | Â |
---|---|---|---|---|
 |  | Median (IQR) | Median (IQR) | P-value†|
Baseline ALT (IU/L) |  | 19 (14–29), n = 185 | 24 (17–32), n = 77 | 0.03 |
Baseline ALP (IU/L) |  | 86 (71–102), n = 187 | 98 (75–135), n = 77 | 0.03 |
Baseline bilirubin (umol/L) | 8 (5–10), n = 185 | 8 (6–12), n = 77 | 0.28 | |
Weight (kg) |  | 61.2 (54.5–69.6), n = 178 | 53.9 (48.0–65.0), n = 74 | 0.001 |
Rifampicin dose per kg | (if given) | 9.68 (8.62–10.7), n = 178 | 9.98 (9.00–11.1), n = 74 | 0.17 |
Isoniazid dose per kg | (if given) | 4.85 (4.31–5.45), n = 178 | 5.57 (4.62–6.25), n = 74 | <0.001 |
Pyrazinamide dose per kg | (if given) | 24.4 (21.4–27.5), n = 178 | 25.8 (22.7–29.8), n = 74 | 0.05 |
Moxifloxacin dose per kg | (if given) | 6.15 (5.71–7.04), n = 21 | 7.67 (5.71–8.00), n = 10 | 0.20 |
 |  | % (fraction) | % (fraction) |  |
HIV positive | Â | 2.2 (4/185) | 7.3 (5/69) | 0.06 |
HCV positive | Â | 1.7 (3/179) | 1.4 (1/73) | 1.00 |
HBV positive | Â | 2.2 (4/180) | 0.0 (0/74) | 0.33 |
Alcohol consumptiona | Nil | 93.3 (167/179) | 71.4 (40/56) | <0.001 |
 | Any | 6.7 (12/179) | 28.6 (16/56) |  |
Chronic Liver Disease | Â | 2.2 (4/186) | 3.9 (3/77) | 0.42 |